Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ironwood Pharmaceuticals (IRWD) Equity Average (2016 - 2025)

Ironwood Pharmaceuticals' Equity Average history spans 15 years, with the latest figure at -$263.0 million for Q4 2025.

  • For Q4 2025, Equity Average rose 14.15% year-over-year to -$263.0 million; the TTM value through Dec 2025 reached -$263.0 million, up 14.15%, while the annual FY2025 figure was -$281.6 million, 153.44% down from the prior year.
  • Equity Average for Q4 2025 was -$263.0 million at Ironwood Pharmaceuticals, up from -$286.2 million in the prior quarter.
  • Across five years, Equity Average topped out at $679.6 million in Q1 2023 and bottomed at -$336.2 million in Q3 2023.
  • The 5-year median for Equity Average is $245.5 million (2021), against an average of $161.0 million.
  • The largest annual shift saw Equity Average soared 3627.52% in 2021 before it tumbled 281.14% in 2024.
  • A 5-year view of Equity Average shows it stood at $592.9 million in 2021, then rose by 4.86% to $621.7 million in 2022, then decreased by 17.2% to $514.8 million in 2023, then plummeted by 159.51% to -$306.3 million in 2024, then rose by 14.15% to -$263.0 million in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Equity Average are -$263.0 million (Q4 2025), -$286.2 million (Q3 2025), and -$321.1 million (Q2 2025).